Ioan Coman

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

SERS-Based Liquid Biopsy of Gastrointestinal Tumors Using a Portable Raman Device Operating in a Clinical Environment

Lucreția Avram, Ștefania D. Iancu, Andrei Ştefancu et al. · Journal of Clinical Medicine · 2020 · 39 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Long-Term Efficacy of <i>Serenoa repens</i> Treatment in Patients with Mild and Moderate Symptomatic Benign Prostatic Hyperplasia

I. Sinescu, P. Geavlete, R. Multescu et al. · Urologia Internationalis · 2011 · 38 citations

Medicine, Pharmacology, Urology +13

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner et al. · Diabetes Care · 2021 · 38 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17